safety of glp-1 receptor agonists Frontiers Holding GLP-1 Agonists Prior to

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

The key players are hydroxytyrosol, oleocanthal, oleacein, and oleuropein derivatives

Over 2.1 years, cardiovascular events were similar between the groups (13% with GLP-1RAs versus 13.8% in DPP-4is

(2017) 312:E224E33

Although past meta-analyses reported substantial reductions in MACE with DPP-4 inhibitors [23], their conclusions were based on studies with small sample sizes and limited numbers of cardiovascular events, which have not been confirmed by the four CVOTs specifically designed to assess the CV safety of DPP-4 inhibitors